The treatment landscape for multiple myeloma continues to evolve as new therapies move earlier into frontline care. In January 2026, the United States Food and Drug Administration approved Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval represents a significant milestone for patients who historically have had fewer frontline treatment options with deep and durable responses.
Darzalex Faspro is a subcutaneous formulation of daratumumab combined with hyaluronidase. With this latest decision, the Darzalex Faspro based D VRd regimen becomes the first and only anti CD38 antibody based quadruplet approved for newly diagnosed multiple myeloma regardless of transplant eligibility. The approval is based on results from the pivotal Phase 3 CEPHEUS trial, which demonstrated improved depth of response and reduced risk of disease progression compared with the long standing standard regimen VRd alone.
This article explores what the FDA approval means, how the regimen works, key clinical trial findings, safety considerations, and the broader implications for multiple myeloma care.
Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow. In this disease, abnormal plasma cells multiply and crowd out healthy blood forming cells, leading to bone damage, anemia, kidney problems, and increased risk of infections.
Autologous stem cell transplant has long been considered a cornerstone of treatment for eligible patients. However, many newly diagnosed patients are older or have other medical conditions that make transplant unsafe or impractical. These patients are considered transplant ineligible and rely entirely on drug based regimens for disease control.
Historically, treatment outcomes for transplant ineligible patients have lagged behind those seen in younger, fitter populations. As a result, there has been a strong clinical need to bring more effective therapies into the frontline setting for this group.
Darzalex Faspro contains daratumumab, a monoclonal antibody that targets CD38, a protein highly expressed on multiple myeloma cells. By binding to CD38, daratumumab helps the immune system identify and destroy cancer cells through several mechanisms, including antibody dependent cellular cytotoxicity and complement mediated cell death.
Unlike intravenous daratumumab, Darzalex Faspro is administered subcutaneously, allowing for shorter administration times and potentially improved patient convenience. It is co formulated with recombinant human hyaluronidase, which enables rapid absorption under the skin.
Darzalex Faspro has already been approved for multiple indications across newly diagnosed, relapsed, refractory, and high risk smoldering multiple myeloma. This latest approval further solidifies its role as a foundational therapy in myeloma treatment.
The newly approved regimen combines Darzalex Faspro with three established agents:
Together, these four drugs attack multiple myeloma through complementary mechanisms. Proteasome inhibition disrupts protein recycling within cancer cells, lenalidomide enhances immune responses and inhibits tumor growth, dexamethasone reduces inflammation and directly kills myeloma cells, and daratumumab targets CD38 on malignant plasma cells.
The use of a quadruplet regimen reflects a growing trend in myeloma care to intensify upfront therapy in order to achieve deeper responses earlier in the disease course.
The FDA approval was based on data from the CEPHEUS study, a randomized, open label Phase 3 trial that enrolled 395 patients across 13 countries. Participants had newly diagnosed multiple myeloma and were either ineligible for transplant or deferred transplant as initial therapy.
Patients were randomized to receive either the D VRd regimen or the standard VRd regimen without daratumumab.
The primary endpoint of the CEPHEUS trial was minimal residual disease negativity at a sensitivity threshold of 10 to the minus 5. Minimal residual disease, or MRD, refers to the presence of very small numbers of cancer cells that remain after treatment and are undetectable by conventional methods.
At a median follow up of 22 months, MRD negativity was achieved in 52.3 percent of patients treated with D VRd compared with 34.8 percent in the VRd group. This difference was statistically significant and clinically meaningful.
With longer follow up of 39 months, nearly double the proportion of patients in the D VRd arm achieved sustained MRD negativity lasting at least 12 months compared with those receiving VRd alone.
Importantly, the addition of Darzalex Faspro reduced the risk of disease progression or death by 40 percent. At nearly five years of follow up, patients receiving D VRd also demonstrated higher rates of complete response or better.
Overall survival data were not yet mature at the time of analysis, but the depth and durability of responses suggest the potential for long term benefit.
The safety profile of Darzalex Faspro in combination with VRd was generally consistent with the known safety profiles of the individual agents.
The most common adverse events observed in patients receiving D VRd included upper respiratory tract infections, peripheral neuropathy, fatigue, diarrhea, musculoskeletal pain, rash, edema, and cough. Serious infections such as pneumonia were reported and require careful monitoring.
Administration related reactions occurred less frequently with the subcutaneous formulation than historically seen with intravenous daratumumab, although systemic and local reactions remain possible. Patients are typically pre medicated and monitored closely, particularly during early doses.
As with other myeloma therapies, blood count suppression including neutropenia and thrombocytopenia may occur, and regular laboratory monitoring is essential.
This approval represents a meaningful advancement for newly diagnosed multiple myeloma patients who are not candidates for transplant. For the first time, these patients have access to an FDA approved anti CD38 antibody based quadruplet regimen in the frontline setting.
The results of the CEPHEUS trial suggest that deeper responses, higher rates of MRD negativity, and prolonged disease control can be achieved without transplant. This may translate into improved quality of life and potentially longer survival for a population with historically limited options.
From a clinical perspective, the approval may help establish D VRd as a new standard of care for transplant ineligible patients, reshaping treatment guidelines and practice patterns worldwide.
Multiple myeloma remains an incurable disease, but outcomes have improved dramatically over the past two decades due to advances in drug development. The trend toward using highly effective combinations earlier in treatment reflects a growing emphasis on achieving the deepest possible remission from the outset.
Ongoing research will determine how best to sequence therapies, how long treatment should continue, and whether MRD guided approaches can further personalize care. The role of Darzalex Faspro in combination regimens is likely to continue expanding as new data emerge.
The FDA approval of Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone marks an important step forward in the treatment of newly diagnosed multiple myeloma patients who are transplant ineligible. Backed by robust Phase 3 data, the D VRd regimen offers deeper and more durable responses compared with standard therapy alone.
As clinicians and patients seek more effective frontline options, this approval underscores the growing importance of immunotherapy based combinations in reshaping the future of multiple myeloma care.
Johnson and Johnson press release. Darzalex Faspro based quadruplet regimen approved by the U.S.
Darzalex Faspro U.S. Prescribing Information and data from the Phase 3 CEPHEUS clinical trial.
This article is for informational and educational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional regarding treatment decisions, medication use, and individual medical conditions. Information is based on publicly available sources at the time of writing and may change as new data emerge.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.